Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.80 |
| ▸ | POLB | P06746 | 8/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.80 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.80 |
| ▸ | GLA | P06280 | 5/20 | 0.80 |
| ▸ | HPGD | P15428 | 5/20 | 0.80 |
| ▸ | GAA | P10253 | 4/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.80 |
| ▸ | ESR1 | P03372 | 1/20 | 0.80 |
| ▸ | TP53 | P04637 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | RECQL | P46063 | 5/20 | 0.65 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | BLM | P54132 | 2/20 | 0.65 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.65 |
| ▸ | APEX1 | P27695 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 6/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312200 | 0.89 | KDM4E (0.80) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL116036 | 0.89 | KDM4E (1.00) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL29703130 | 0.89 | KDM4E (1.00) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL4472928 | 0.87 | KDM4E (0.97) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL28520534 | 0.86 | KDM4E (0.80) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL3331112 | 0.80 | UBE2I (0.78) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL1898779 | 0.79 | KDM4E (0.76) | KDM4EPOLBMEN1KMT2ALMNA | |
| SCHEMBL13957895 | 0.78 | SIRT6 (0.66) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL23722921 | 0.78 | CACNA1B (0.75) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL10757465 | 0.78 | KDM4E (0.73) | KDM4EPOLBMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482458-B2 | Quinoline derivatives | SMITHKLINE BEECHAM FARMACEUTICA S.P.A. (IT) | 2009-01-27 | — | — | US | disclosed |
| US-20060160846-A1 | Quinoline derivatives | SMITHKLINE BEECHAM FARMAEUTICI S.P.A. | 2006-07-20 | — | — | US | disclosed |
| US-20050096316-A1 | Neutokinin (NK3) receptor antagonists; pulmonary disorders, nervous system disorders and neurodegenerative disorders | FARINA CARLO (IT) | 2005-05-05 | — | — | US | disclosed |
| EP-0940391-B1 | Quinoline derivatives as tachykinin NK3 receptor antagonists | GLAXOSMITHKLINE SPA (IT) | 2004-08-18 | — | — | EP | disclosed |
| US-6743804-B2 | A QUINOLINE DERIVATIVES, FOR TREATMENT OF CERTAIN CONDITIONS BY OVERSTIMULATION OF THE THACHYKININ RECEPTORS, DISORDERS OF CENTRAL NERVOUS SYSTEM, SCHIZOPHRENIA; NEURODEGENERATIVE DISORDERS ALZHEIMER DISEASE AND DOWN'S SYNDROME | SMITHKLINE BEECHAM S P.A. (IT) | 2004-06-01 | — | — | US | disclosed |
| US-20030236281-A1 | Quinoline derivatives(2) | FARINA CARLO (IT) | 2003-12-25 | — | — | US | disclosed |
| US-20030195204-A1 | Quinoline derivatives as NK3 antagonists | SMITHKLINE BEECHAM S.P.A. | 2003-10-16 | — | — | US | disclosed |
| US-6608083-B1 | Treatment and/or prophylaxis of convulsive disorders, renal disorders, urinary incontinence, ocular inflammation, eating disorders, inflammatory pain, allergic rhinitis, psoriasis,neurodegenerative disorders, Huntington's disease, | SMITHKLINE BEECHAM FARMACEUTICI S.P.A (IT) | 2003-08-19 | — | — | US | disclosed |
| EP-0804419-B1 | QUINOLINE DERIVATIVES AS TACHYKININ NK 3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM FARMA (IT) | 2003-08-06 | — | — | EP | disclosed |
| CN-1428145-A | Quinoline derivative as tachykinin NK3 receptor agonist | SMITHKLINE BEECHEM CORP (IT) | 2003-07-09 | — | — | CN | disclosed |
| EP-0874827-B1 | QUINOLINE DERIVATIVES AS NK3 ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2003-05-21 | — | — | EP | disclosed |
| CN-1092642-C | Use as tachykinin NK3Quinoline derivatives of receptor antagonists | SMITHKLINE BEECHAM FARMA (IT) | 2002-10-16 | — | — | CN | disclosed |
| CN-1276211-A | Use of non-peptides NK3-antagonist | SMITHKINE BEECHEM S P A (IT) | 2000-12-13 | — | — | CN | disclosed |
| EP-0940391-A2 | Quinoline derivatives as tachykinin NK3 receptor antagonists | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1999-09-08 | — | — | EP | disclosed |
| EP-0874827-A1 | QUINOLINE DERIVATIVES AS NK3 ANTAGONISTS | Smithkline Becham S.P.A. (IT) | 1998-11-04 | — | — | EP | disclosed |
| US-5811553-A | TREATMENT OF NEURODEGENERATIVE DISORDERS, PULMONARY DISORDERS | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1998-09-22 | — | — | US | disclosed |
| EP-0804419-A1 | QUINOLINE DERIVATIVES AS TACHYKININ NK 3 RECEPTOR ANTAGONISTS | SmithKline Beecham Farmaceutici S.p.A. (IT) | 1997-11-05 | — | — | EP | disclosed |
| CN-1156451-A | Use as tachykinin NK3Quinoline derivatives of receptor antagonists | SMITHKLINE BEECHAM FARMA (IT) | 1997-08-06 | — | — | CN | disclosed |
| WO-1997019927-A1 | QUINOLINE DERIVATIVES AS NK3 ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 1997-06-05 | — | — | WO | disclosed |
| WO-1995032948-A1 | QUINOLINE DERIVATIVES AS TACHYKININ NK3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1995-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195204-A1 | Quinoline derivatives as NK3 antagonists | KCNK3, KCND3, KCNN3 | KDM4E 1779/4885POLB 4503/4885TDP1 3947/4885 |
| US-20060160846-A1 | Quinoline derivatives | CHRNA3, CHRNB3, KCNQ3 | KDM4E 3752/4885POLB 3549/4885TDP1 2366/4885 |
| US-20030236281-A1 | Quinoline derivatives(2) | KCNQ3, CHRNA3, KCNK3 | KDM4E 3770/4885POLB 2643/4885TDP1 1318/4885 |
| US-20050096316-A1 | Neutokinin (NK3) receptor antagonists; pulmonary disorders, nervous system disorders and neurodegenerative disorders | TACR3, CHRNB3, CHRNA3 | KDM4E 4500/4885POLB 4303/4885TDP1 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.